SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples (original) (raw)
Senderowicz AM, Sausville EA (2000) Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92:376–387 ArticlePubMedCAS Google Scholar
Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783 ArticlePubMedCAS Google Scholar
Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408–9421 ArticlePubMedCAS Google Scholar
Sharma SV, Fischbach MA, Haber DA, Settleman J (2006) “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12:4392–4395 Article Google Scholar
Wickremasinghe RG, Hoffbrand AV (1999) Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 93:3587–3600 PubMedCAS Google Scholar
Belinda C, Baliga SK (2002) Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 20:63–74 Article Google Scholar
Wuilleme-Toumi S, Robillard N, Gomez P et al (2005) Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19:1248–1252 ArticlePubMedCAS Google Scholar
MacCallum DE, Melville J, Frame S et al (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of rna polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399–5407 ArticlePubMedCAS Google Scholar
Derenne S, Monia B, Dean NM et al (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 100:194–199 ArticlePubMedCAS Google Scholar
Nurse P (2002) Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep 22:487–499 ArticlePubMedCAS Google Scholar
Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann Rev Cell Develop Biol 13:261–291 ArticleCAS Google Scholar
Mailand N, Diffley J (2005) CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122:915–926 ArticlePubMedCAS Google Scholar
Harper JW, Elledge SJ (1998) The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev 12:285–289 ArticlePubMedCAS Google Scholar
Kaldis P, Russo AA, Chou HS, Pavletich NP, Solomon MJ (1998) Human and yeast Cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 9:2545–2560 PubMedCAS Google Scholar
Fesquet D, Morin N, Doree M, Devault A (1997) Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts? Oncogene 15:1303–1307 ArticlePubMedCAS Google Scholar
Akoulitchev S, Makela T, Weinberg R, Reinberg D (1995) Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature 377:557–560 ArticlePubMedCAS Google Scholar
Busso D, Keriel A, Sandrock B et al (2000) Distinct regions of MAT1 regulate cdk7 kinase and TFIIH transcription activities. J Biol Chem 275:22815–22823 ArticlePubMedCAS Google Scholar
Hirose Y, Ohkuma Y (2007) Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem Tokyo 141:601–608 PubMedCAS Google Scholar
Lee TI, Young RA (2000) Transcription of eukaryotic protein-coding genes. Annu Rev Genet 34:77–137 ArticlePubMedCAS Google Scholar
Misra RN, H-y Xiao, Kim KS et al (2004) _N_-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. _N_-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719–1728 ArticlePubMedCAS Google Scholar
Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105:1383–1395 ArticlePubMedCAS Google Scholar
Yasui H, Hideshima T, Richardson P, Anderson K (2006) Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol 7:381–393 ArticlePubMedCAS Google Scholar
Frassanito MA, Cusmai A, Iodice G, Dammacco F (2001) Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97:483–489 ArticlePubMedCAS Google Scholar
Chao S-H, Fujinaga K, Marion JE et al (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275:28345–28348 ArticlePubMedCAS Google Scholar
Bach S, Knockaert M, Reinhardt J et al (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280:31208–31219 ArticlePubMedCAS Google Scholar
Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-dependent Kinase (CDK) 2 and CDK4 in Human Breast Carcinoma Cells. Cancer Res 56:2973–2978 PubMedCAS Google Scholar
Losiewicz M, Carlson B, Kaur G, Sausville E, Worland P (1994) Potent inhibition of CDC2 kinase activity by the flavonoid L86–8275. Biochem Biophys Res Commun 201:589–595 ArticlePubMedCAS Google Scholar
McClue S, Blake D, Clarke R et al (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102:463–468 ArticlePubMedCAS Google Scholar
Squires MS, Feltell RE, Lock V et al (2007) AT7519, a potent CDK inhibitor, is active in leukemia models and primary CLL patient samples. ASH Annual Meeting Abstracts 110:3127 Google Scholar
Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513–2519 ArticlePubMedCAS Google Scholar
Merino R, Ding L, Veis D, Korsmeyer S, Nunez G (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13:683–691 PubMedCAS Google Scholar
Byrd JC, Lin TS, Dalton JT et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399–404 ArticlePubMedCAS Google Scholar
Bible KC, Lensing JL, Nelson SA et al (2005) Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 11:5935–5941 ArticlePubMedCAS Google Scholar
Chen R, Wierda WG, Benaissa S et al (2007) Mechanism of Action of SNS–032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. ASH Annual Meeting Abstracts 110:3112 Google Scholar
Heath E, Bible K, Martell R, Adelman D, Lorusso P (2008) A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59–65 ArticlePubMedCAS Google Scholar
Hawtin RE, Cohen R, Haas N et al (2007) In: 12th congress of the European Hematology Association Vienna, Austria, June 7–10, 2007. Haematologica, p 276
Goldberg Z, Wierda W, Chen R et al (2008) In: 13th congress of the European Hematology Association Copenhagen, Denmark, June 12–15, 2008. Haematologica, p 327
Bergsagel P (2007) Individualizing therapy using molecular markers in multiple myeloma. Clin Lymphoma Myeloma 7(Suppl 4):S170–S174 ArticlePubMedCAS Google Scholar
Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108:2020–2028 ArticlePubMedCAS Google Scholar
Ali M, Choy H, Habib A, Saha D (2007) SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 9:370–381 ArticlePubMedCAS Google Scholar
Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296–303 ArticlePubMedCAS Google Scholar
Trudel S, Sebag M, Li ZH et al (2008) SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical activity in human multiple myeloma. AACR Meeting Abstracts 2008, p 4972
Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815 ArticlePubMedCAS Google Scholar